July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • Nadim Rayess
    USC Roski Eye Institute , Los Angeles, California, United States
  • Ehsan Rahimy
    Palo Alto Retina Group, Palo Alto, California, United States
  • Gui-Shuang Ying
    Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Maria Pefkianaki
    Wills Eye Institute, Philadelphia, Pennsylvania, United States
  • Carl Regillo
    Wills Eye Institute, Philadelphia, Pennsylvania, United States
  • allen ho
    Wills Eye Institute, Philadelphia, Pennsylvania, United States
  • Jason Hsu
    Wills Eye Institute, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Nadim Rayess, None; Ehsan Rahimy, None; Gui-Shuang Ying, None; Maria Pefkianaki, None; Carl Regillo, genentech (C), Genentech (F); allen ho, Genentech (C), Genentech (F); Jason Hsu, Ophthotech (F), Santen (F), Xoma (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4291. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nadim Rayess, Ehsan Rahimy, Gui-Shuang Ying, Maria Pefkianaki, Carl Regillo, allen ho, Jason Hsu; Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4291.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the association between subfoveal choroidal thickness (SFCT) and branch retinal vein occlusion (BRVO) eyes treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Since the choroid plays a primary role in perfusing the outer retina and photoreceptors, the primary objective of our study was to evaluate initial choroidal thickness as a predictor for visual recovery in patients with macular edema secondary to BRVO.

Methods : This was a retrospective consecutive case series of patients who were newly diagnosed with treatment naïve BRVO and treated with 3 monthly anti-VEGF injections at the Wills Eye Institute. All patients received enhanced depth imaging spectral domain optical coherence tomography scans to determine SFCT and central macular thickness (CMT). Baseline predictors (particularly SFCT) for functional response (best-corrected visual acuity gain ≥2 lines) were assessed at 3 months follow up using univariate and multivariate analysis.

Results : A total of 40 eyes from 39 patients were included. Mean baseline SFCT was higher in functional responders (240.4 ± 73.1µm), compared to both non-responders (193.3 ± 63.6 µm; P=0.036) and their corresponding fellow eye (202.2 ± 67.1 µm; P=0.022). However, there was no difference in baseline SFCT between the non-responder BRVO eyes and their fellow eye (195.5 ± 62.0 µm; P=0.876). A higher baseline SFCT (for every 100 µm increase in SFCT) was found to be a positive predictor for functional response (regression coefficient: 1.1; P=0.03) on univariate analysis but not multivariate analysis.

Conclusions : Treatment-naïve patients with BRVO who have a thicker baseline choroidal thickness compared to their fellow eye were more likely to have improved short-term visual outcomes following anti-VEGF therapy compared to patients with an initial choroidal thickness that is similar to their fellow eye. One hypothesis is that patients with a greater initial choroidal thickness are more likely to have intact perfusion to the outer retinal layers and therefore have a greater potential for visual gains following treatment of macular edema. Conversely, a thinner baseline choroidal thickness may be indicative of a more ischemic process and poorer perfusion to the outer retinal layers with less potential for visual recovery. Thus, initial SFCT may be a predictor for visual outcomes in patients receiving anti-VEGF therapy for BRVO.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×